Contact Us
Phase-Xs | Biologics & Biosimilars | Coherent Market Insights

Impact Analysis of Covid-19

The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.

Androgenetic alopecia (AGA) is a patterned hair loss occurring due to systemic androgen and genetic factors. It is the most common cause of hair loss in both genders. It is characterized by follicular miniaturization in a patterned hair loss occurring due to systemic androgen and genetic factors. The increasing incidence of androgenetic alopecia is expected to boost the market growth. According to the National Center for Biotechnology Information (NCBI), in August 2015, global prevalence of severe androgenetic alopecia (AGA) was 15.33% overall and varied significantly by geographical region. The risk of having severe androgenetic alopecia (AGA) increased by 1.092 for per year for the 30 and 40 age group.

The global androgenetic alopecia treatment market is estimated to be valued at US$ 1,607.47 million in 2020 and is expected to exhibit a CAGR of 5.2% during the forecast period (2020-2027).

Figure 1. Global Androgenetic Alopecia Treatment Market Share (%), by Region, 2020

Androgenetic Alopecia Treatment  | Coherent Market Insights

Product development and ongoing clinical trials are expected to propel growth of the global androgenetic alopecia treatment market.

Development of drugs for androgenetic alopecia treatment is expecting to boost the market growth over the forecast period. For instance, Cairo University is conducting clinical trial of topical Cetirizine for the treatment of androgenetic alopecia in females. The trial is in Phase II/III evaluating the efficacy and tolerability of topical cetirizine in female patients with androgenetic alopecia (AGA). This interventional trial started in February 2020 and the study expected completed in December 2021. 

However, side effects of androgenetic alopecia treatment are expected to hinder the market growth. According to the US Pharmacist, a clinically-focused pharmacy publication, published an article- Treatment Options for Androgenetic Alopecia, in 2018 that medication used in for the treatment of androgenetic alopecia has many side effects. For example, topical Minoxidil can cause local erythema and pruritus and Finasteride can cause dizziness, orthostatic hypotension and others.

request-sample

Androgenetic Alopecia Treatment Market Report Coverage

Report Coverage Details
Base Year: 2019 Market Size in 2020: US$ 1,607.47 Mn
Historical Data for: 2016 to 2019 Forecast Period: 2020 to 2027
Forecast Period 2020 to 2027 CAGR: 5.3% 2027 Value Projection: US$ 2,298.34 Mn
Geographies covered:
  • North America: U.S. and Canada
  • Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
  • Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
  • Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
  • Middle East: GCC Countries, Israel, and Rest of Middle East
  • Africa: South Africa, North Africa, and Central Africa
Segments covered:
  • By Drug Type: Topical Agents, 5 AR Inhibitors, Others.
  • By Route of Administration: Oral, Topical.
  • By Gender: Male, Female.
  • By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies.
Companies covered:

Histogen Inc., Cipla Limited, Aclaris Therapeutics, Inc., Merck & Co., Inc., Daiichi-Sankyo Co., Ltd., Johnson and Johnson Services, Inc., Lexington International LLC, Vita-Cos-Med Klett-Loch GmbH, PureTech, Vitabiotics, Dr. Reddy’s Laboratories, HCell Inc., Follica, Inc. and Ranbaxy Laboratories Ltd.

Growth Drivers:
  • Rising incidence of androgenetic alopecia
  • Product development and ongoing trials for treatment of androgenetic alopecia
Restraints & Challenges:
  • Side effects of androgenetic alopecia treatment
  • Alternative treatment for androgenetic alopecia treatment

Figure 2. Global Androgenetic Alopecia Treatment Market Share (%), by Drug Type, 2020

Androgenetic Alopecia Treatment  | Coherent Market Insights

Research and development of treatment for androgenetic alopecia in North America is expected to boost the market growth.

North America is expected to hold dominant position in the global androgenetic alopecia treatment market owing to research and development of treatments for androgenetic alopecia in the region. For instance, on June 4, 2020, Follica, Inc., a biotechnology company developing a regenerative platform designed to treat androgenetic alopecia, and other related conditions, announced positive feedback from the U.S. Food and Drug Administration (FDA) for its FOL-004 Phase II released in December 2019. The company advanced its lead program, FOL-004 into Phase III development, following a successful safety and efficacy optimization study for the treatment of hair loss in male androgenetic alopecia.

Global Androgenetic Alopecia Treatment Market – Impact of Coronavirus (COVID-19) Pandemic

Nationwide lockdowns resulting from COVID-19 in various countries across the globe have impacted the financial status of businesses in all sectors. The private healthcare is one such sector which has been impacted significantly by the COVID-19 pandemic.

The lockdown in various countries due to the pandemic has placed an economic burden on the healthcare sector. Moreover, the coronavirus pandemic has hampered the development, production, and supply of drugs and other healthcare products and affected growth of healthcare businesses of various companies across the globe.

As a result, the impact of the COVID-19 pandemic is also expected to limit growth of the global androgenetic alopecia treatment drugs market during the forecast period.

Key Players

Major players operating in the global androgenetic alopecia treatment market are Histogen Inc., Cipla Limited, Aclaris Therapeutics, Inc., Merck & Co., Inc., Daiichi-Sankyo Co., Ltd., Johnson and Johnson Services, Inc., Lexington International LLC, Vita-Cos-Med Klett-Loch GmbH, PureTech, Vitabiotics, Dr. Reddy’s Laboratories, HCell Inc., Follica, Inc. and Ranbaxy Laboratories Ltd. among others.

Androgenetic alopecia, a slow progressive form of alopecia, begins after the onset of puberty. Pattern or androgenetic alopecia is a genetically predetermined disorder due to excessive response to androgens that affects up to 50% of males and females globally, according to the National Center for Biotechnology Information (NCBI). It is characterized by progressive loss of terminal hair of the scalp, in a characteristic distribution in both males and females. In males, hair loss is most prominent in the vertex and frontotemporal regions, while in women the frontal hairline is typically spared with diffuse apical hair loss noted as a wider anterior part of the hair.

Market Dynamics

Rising incidence of androgenetic alopecia is expected to drive the global androgenetic alopecia treatment market growth. According to the National Library of Medicine (NLM), a medical library which is part of the National Institutes of Health (NIH), androgenetic alopecia affects approximately 50 million men and 30 million women in the U.S.

However, availability of alternative treatments is expected to hinder the market growth. For instance, hair restoration surgery such as scalp reduction surgeries, which is not used frequently but efficacy of hair transplantation is based on the principle of donor dominance.

Key features of the study:

  • This report provides in-depth analysis of the global androgenetic alopecia treatment  market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2020–2027), considering 2019 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new drug launches or approval, market trends,  regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global androgenetic alopecia treatment  market based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
  • Key companies covered as a part of this study are Histogen Inc., Cipla Limited, Aclaris Therapeutics, Inc., Merck & Co., Inc., Daiichi-Sankyo Co., Ltd., Johnson and Johnson Services, Inc., Lexington International LLC, Vita-Cos-Med Klett-Loch GmbH, PureTech, Vitabiotics, Dr. Reddy’s Laboratories, HCell Inc., Follica, Inc. and Ranbaxy Laboratories Ltd. among others
  • Insights from this report would allow marketers and management authorities of companies to make informed decisions regarding future drug launches, drug class up-gradation, market expansion, and marketing tactics
  • The global androgenetic alopecia treatment market report caters to various stakeholders in this industry including investors, suppliers, manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global androgenetic alopecia treatment market.

Detailed Segmentation:

  • Global Androgenetic Alopecia Treatment Market, By Drug Type:
    • Topical Agents
    • 5 AR Inhibitors
    • Others
  • Global Androgenetic Alopecia Treatment  Market, By Route of Administration:
    • Oral
    • Topical
  • Global Androgenetic Alopecia Treatment  Market, By Gender:
    • Male
    • Female
  • Global Androgenetic Alopecia Treatment  Market, By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Global Androgenetic Alopecia Treatment  Market, By Region:
    • North America
      • By Drug Type:
        • Topical Agents
        • 5 AR Inhibitors
        • Others
      • By Route of Administration:
        • Oral
        • Topical
      • By Gender:
        • Male
        • Female
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country:
        • U.S.
        • Canada
    • Latin America
      • By Drug Type:
        • Topical Agents
          • 5 AR Inhibitors
          • Corticosteroids
          • Others
      • By Route of Administration:
        • Oral
        • Topical
        • Injectable
      • By Gender:
        • Male
        • Female
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country:
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • By Drug Type:
        • Topical Agents
          • 5 AR Inhibitors
          • Corticosteroids
          • Others
      • By Route of Administration:
        • Oral
        • Topical
        • Injectable
      • By Gender:
        • Male
        • Female
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country:
        • Germany
        • U.K.
        • France
        • Italy
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • By Drug Type:
        • Topical Agents
          • 5 AR Inhibitors
          • Corticosteroids
          • Others
      • By Route of Administration:
        • Oral
        • Topical
        • Injectable
      • By Gender:
        • Male
        • Female
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country:
        • China
        • India
        • Japan
        • Australia
        • South Korea
        • ASEAN
        • Rest of Asia Pacific
    • Middle East
      • By Drug Type:
        • Topical Agents
          • 5 AR Inhibitors
          • Corticosteroids
          • Others
      • By Route of Administration:
        • Oral
        • Topical
        • Injectable
      • By Gender:
        • Male
        • Female
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country:
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • By Drug Type:
        • Topical Agents
          • 5 AR Inhibitors
          • Corticosteroids
          • Others
      • By Route of Administration:
        • Oral
        • Topical
        • Injectable
      • By Gender:
        • Male
        • Female
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country/Region:
        • South Africa
        • Central Africa
        • North Africa
  • Company Profiles
    • Histogen Inc.*
      • Company Overview
      • Product Portfolio
      • Financial Performance
      • Key Highlights
      • Market Strategies
    • Cipla Limited
    • Aclaris Therapeutics, Inc.
    • Merck & Co., Inc.
    • Daiichi-Sankyo Co., Ltd.
    • Johnson and Johnson Services, Inc.
    • Lexington International LLC
    • Vita-Cos-Med Klett-Loch GmbH
    • PureTech
    • Vitabiotics
    • Reddy’s Laboratories
    • Ranbaxy Laboratories Ltd
    • HCell Inc.
    • Follica, Inc.

“*” marked represents similar segmentation in other categories in the respective section.

Table of Contents

  1. Research Objectives and Assumptions
    • Research Objectives
    • Assumptions
    • Abbreviations
  2. Market Purview
    • Report Description
      • Market Definition and Scope
    • Executive Summary
      • Market Snippet, By Drug Type
      • Market Snippet, By Route of Administration
      • Market Snippet, By Gender
      • Market Snippet, By Distribution Channel
      • Market Snippet, By Region
    • Coherent Opportunity Map (COM)
  3. Market Dynamics, Regulations, and Trends Analysis
    • Market Dynamics
      • Drivers
      • Restraints
      • Market Opportunities
    • Impact Analysis
    • Pipeline Analysis
    • Reimbursement Scenario
    • Epidemiology
    • Pest Analysis
    • Regulatory Scenario
    • New Product Launches
    • Collaborations and Agreements
    • Market Trends
  4. Global Androgenetic Alopecia Treatment Market – Impact of Coronavirus (COVID-19) Pandemic
    • COVID-19 Market Scenario
    • Impact of COVID-19 Market on the Androgenetic Alopecia Treatment Products
  5. Global Androgenetic Alopecia Treatment Market, By Drug Type, 2016–2027, (US$ Mn)
    • Introduction
      • Market Share Analysis, 2020 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017 – 2027
      • Segment Trends
    • Topical Agents
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016–2027, (US$ Mn)
    • 5 AR Inhibitors
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016–2027, (US$ Mn)
    • Others
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016–2027, (US$ Mn)
  6. Global Androgenetic Alopecia Treatment Market, By Route of Administration, 2016–2027, (US$ Mn)
    • Introduction
      • Market Share Analysis, 2020 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017 – 2027
      • Segment Trends
    • Oral
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016–2027, (US$ Mn)
    • Topical
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016–2027, (US$ Mn)
  7. Global Androgenetic Alopecia Treatment Market, By Gender, 2016–2027, (US$ Mn)
    • Introduction
      • Market Share Analysis, 2020 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017 – 2027
      • Segment Trends
    • Male
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016–2027, (US$ Mn)
    • Female
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016–2027, (US$ Mn)
  8. Global Androgenetic Alopecia Treatment Market, By Distribution Channel, 2016–2027, (US$ Mn)
    • Introduction
      • Market Share Analysis, 2020 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017 – 2027
      • Segment Trends
    • Hospital Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016–2027, (US$ Mn)
    • Retail Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016–2027, (US$ Mn)
    • Online Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016–2027, (US$ Mn)
  9. Global Androgenetic Alopecia Treatment Market, By Region, 2016–2027, (US$ Mn)
    • Introduction
      • Market Share Analysis, By Region, 2020 and 2027 (%)
      • Y-o-Y Growth Analysis, For Regions, 2017–2027
    • North America
      • Market Size and Forecast, By Drug Type, 2016–2027, (US$ Mn)
      • Market Size and Forecast, By Route of Administration, 2016–2027, (US$ Mn)
      • Market Size and Forecast, By Gender, 2016–2027, (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2016–2027, (US$ Mn)
      • Market Size and Forecast, By Country, 2016–2027, (US$ Mn)
        • U.S.
        • Canada
    • Latin America
      • Market Size and Forecast, By Drug Type, 2016–2027, (US$ Mn)
      • Market Size and Forecast, By Route of Administration, 2016–2027, (US$ Mn)
      • Market Size and Forecast, By Gender, 2016–2027, (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2016–2027, (US$ Mn)
      • Market Size and Forecast, By Country, 2016–2027, (US$ Mn)
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • Market Size and Forecast, By Drug Type, 2016–2027, (US$ Mn)
      • Market Size and Forecast, By Route of Administration, 2016–2027, (US$ Mn)
      • Market Size and Forecast, By Gender, 2016–2027, (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2016–2027, (US$ Mn)
      • Market Size and Forecast, By Country, 2016–2027, (US$ Mn)
        • Germany
        • U.K.
        • France
        • Italy
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • Market Size and Forecast, By Drug Type, 2016–2027, (US$ Mn)
      • Market Size and Forecast, By Route of Administration, 2016–2027, (US$ Mn)
      • Market Size and Forecast, By Gender, 2016–2027, (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2016–2027, (US$ Mn)
      • Market Size and Forecast, By Country, 2016–2027, (US$ Mn)
        • China
        • India
        • Japan
        • Australia
        • South Korea
        • ASEAN
        • Rest of Asia Pacific
    • Middle East
      • Market Size and Forecast, By Drug Type, 2016–2027, (US$ Mn)
      • Market Size and Forecast, By Route of Administration, 2016–2027, (US$ Mn)
      • Market Size and Forecast, By Gender, 2016–2027, (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2016–2027, (US$ Mn)
      • Market Size and Forecast, By Country, 2016–2027, (US$ Mn)
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • Market Size and Forecast, By Drug Type, 2016–2027, (US$ Mn)
      • Market Size and Forecast, By Route of Administration, 2016–2027, (US$ Mn)
      • Market Size and Forecast, By Gender, 2016–2027, (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2016–2027, (US$ Mn)
      • Market Size and Forecast, By Country/Region, 2016–2027, (US$ Mn)
        • South Africa
        • Central Africa
        • North Africa
  10. Competitive Landscape
    • Heat Map Analysis
    • Market Share Analysis
      • Histogen Inc.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Cipla Limited
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Aclaris Therapeutics, Inc.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Merck & Co., Inc.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Daiichi-Sankyo Co., Ltd.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Johnson and Johnson Services, Inc.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Lexington International LLC
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Vita-Cos-Med Klett-Loch GmbH
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • PureTech
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Vitabiotics
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Reddy’s Laboratories
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Ranbaxy Laboratories Ltd
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • HCell Inc.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Follica, Inc.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
    • Analyst Views
  11. Section
    • References
    • Research Methodology
    • About us and Sales Contact

*Browse 40 market data tables and 35 figures on "Androgenetic Alopecia Treatment Market” - Global forecast to 2027

FAQgrowicon

Frequently Asked Questions

The global androgenetic alopecia treatment market is expected to exhibit a CAGR of 5.2% during the forecast period (2020-2027).
The global androgenetic alopecia treatment market is estimated to be valued at US$ 1,607.47 million in 2020.
Rising incidence of androgenetic alopecia and ongoing clinical trials for the treatment of androgenetic alopecia are favoring the market growth.
The topical agents segment is expected to be the leading drug type segment in the global androgenetic alopecia treatment market during the forecast period (2020-2027).
North America holds the largest market share in the global androgenetic alopecia treatment market.
Major players operating in the global androgenetic alopecia treatment market are Histogen Inc., Cipla Limited, Aclaris Therapeutics, Inc., Merck & Co., Inc., Daiichi-Sankyo Co., Ltd., Johnson and Johnson Services, Inc., Lexington International LLC, Vita-Cos-Med Klett-Loch GmbH, PureTech, Vitabiotics, Dr. Reddy’s Laboratories, HCell Inc., Follica, Inc. and Ranbaxy Laboratories Ltd. among others.
Existing Clientele

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients

Our Trusted Patner

Subscribe Newsletter

Kindly Subscribe for our latest news & articles.